Endolysosomal Sequestration Effects Controlled Release of BRAF Paradox Breaker Nanoparticles
Related Experiment Video
Updated: Jan 17, 2026
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Chen Chen1,2,3, Ana Marie Perea Del Angel1, Ramya Sridharan1,2
1Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Abstract:
BRAF remains one of the most important therapeutic targets in cancer, but BRAF inhibitors can cause "paradoxical" pathway activation and drug resistance through RAF dimerization. A clinical "paradox breaker" inhibitor of BRAF monomers and dimers can potentially evade drug resistance. However, patients are required to receive a high oral daily drug dose to achieve the target therapeutic window. Co-administration of a cytochrome P450 blocker can improve drug exposure, but the combination can lead to drug-drug interactions. We investigated delivery via fucoidan-based nanocarriers to improve pharmacologic properties. We found that the nanoparticles extended BRAF inhibition in cancer cells due to sequestration into endolysosomes, followed by controlled release from a lysosomal depot. Following intraperitoneal administration, nanoparticles improved drug pharmacokinetics in vivo without inhibiting cytochrome P450 and also resulted in substantial improvements in antitumor efficacy. This work describes a general nanotherapeutic strategy to improve the pharmacologic properties of drugs via intracellular depot formation.
Insights
This study introduces fucoidan-based nanocarriers to overcome BRAF inhibitor resistance and improve cancer treatment. The nanocarriers enhance drug delivery and antitumor efficacy without harmful drug interactions.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- BRAF inhibitors are crucial cancer therapeutics but face challenges like paradoxical pathway activation, drug resistance via RAF dimerization, and high dosing requirements.
- Current strategies like cytochrome P450 blockers improve drug exposure but risk drug-drug interactions.
- Developing novel drug delivery systems is essential to enhance BRAF inhibitor efficacy and patient outcomes.
Purpose of the Study:
- To investigate the potential of fucoidan-based nanocarriers for improving the pharmacologic properties of BRAF inhibitors.
- To assess the efficacy of nanocarrier-delivered BRAF inhibitors in overcoming drug resistance and enhancing antitumor activity.
- To evaluate the in vivo pharmacokinetics and safety profile of the nanotherapeutic strategy.
Main Methods:
- Fabrication and characterization of fucoidan-based nanocarriers encapsulating a BRAF inhibitor.
- In vitro assessment of BRAF inhibition, cellular uptake, and drug release mechanisms in cancer cells.
- In vivo pharmacokinetic studies and evaluation of antitumor efficacy following intraperitoneal administration in a preclinical cancer model.
Main Results:
- Nanoparticles demonstrated prolonged BRAF inhibition in cancer cells through endolysosomal sequestration and controlled lysosomal release.
- Intraperitoneal administration of nanoparticles improved drug pharmacokinetics in vivo without affecting cytochrome P450 activity.
- Significant improvements in antitumor efficacy were observed with the nanocarrier-based drug delivery system.
Conclusions:
- Fucoidan-based nanocarriers represent a promising strategy to enhance BRAF inhibitor pharmacologic properties, overcoming resistance mechanisms.
- This nanotherapeutic approach improves drug exposure and antitumor efficacy while avoiding cytochrome P450-mediated drug-drug interactions.
- The development of intracellular depot-forming nanocarriers offers a generalizable strategy for improving the therapeutic potential of various drugs.
